|
시장보고서
상품코드
2128107
분산형 임상시험 시장 규모, 점유율, 성장 및 세계 업계 분석, 지역별 동향 및 예측(2026-2034년)Decentralized Clinical Trials Market Size, Share, Growth and Global Industry Analysis, Regional Insights and Forecast to 2026-2034 |
||||||
분산형 임상시험 시장의 성장 요인
전 세계 분산형 임상시험 시장은 2025년에 95억 6,000만 달러 규모에 달하며, 2026년 109억 2,000만 달러에서 2034년에는 293억 7,000만 달러로 확대될 전망이며, 예측 기간 중 연평균 성장률(CAGR)은 13.2%에 달할 것으로 전망됩니다. 북미는 디지털 헬스케어 기술의 보급, 첨단인 임상 연구 인프라, 원격 임상시험 솔루션에 대한 투자 확대에 힘입어 2025년 42.46%라는 최대 시장 점유율을 차지했습니다.
분산형 임상시험(DCT)에서는 디지털 플랫폼, 원격의료, 웨어러블 기기, 원격 환자 모니터링, 전자 동의(eConsent), 전자 환자 보고 결과(ePRO)를 활용함으로써 임상시험 활동의 일부 또는 전부를 기존 연구 시설 밖에서 수행하는 것이 가능해집니다. 만성질환 유병률의 증가, 암 및 희귀 질환에 대한 연구 확대, 환자 중심 연구 모델의 부상, 그리고 인공지능(AI) 활용 확대가 전 세계에서 분산형 임상시험의 도입을 가속화하고 있습니다.
시장 동향
인공지능(AI) 통합이 진행됨에 따라 환자 모집, 시험 매칭, 원격 모니터링, 예측적 피험자 등록 및 참가자 유지율이 향상되면서 분산형 임상시험은 혁신을 이루고 있습니다. AI를 활용한 분석을 통해 임상시험 의뢰자는 전자 건강 기록, 유전체 데이터베이스 및 RWE(Real-World Evidence)를 분석하여 적격 참가자를 보다 효율적으로 식별할 수 있게 됩니다. 원격의료, 웨어러블 헬스 기기, 원격 모니터링 플랫폼, 디지털 데이터 수집 툴 역시 분산형 임상시험의 표준 구성 요소로 자리 잡고 있으며, 환자의 부담을 줄이는 동시에 연구 효율 향상에 기여하고 있습니다. 터프츠 대학교 의과대학에 따르면 2025년에는 AI를 활용한 임상시험 활동을 통해 약 18%의 시간 단축이 실현되었다고 하며, 이는 임상 연구에서 지능형 디지털 솔루션의 중요성이 점점 더 커지고 있음을 여실히 보여주고 있습니다.
시장 촉진요인
만성질환, 종양학, 희귀 질환에 관한 임상 연구의 증가는 시장 확장을 지원하는 주요 촉진요인 중 하나입니다. 이러한 연구에서는 대개 지속적인 환자 모니터링, 더 광범위한 지역의 참여, 그리고 장기적인 추적 조사가 필요하므로 분산형 임상시험 모델이 매우 효과적입니다. 미국 국립생물공학정보센터(NCBI)에 따르면 2026년에는 전 세계에서 약 58만 6,665건의 임상시험이 등록될 것으로 예상되며, 이는 효율적인 임상시험 관리 솔루션에 대한 수요가 증가하고 있음을 시사합니다. 의료비 증가, 제약사의 연구 파이프라인 확대, 맞춤형 의료에 대한 노력, 그리고 대형 CRO(의약품 개발 수탁 기관)의 투자 증가도 시장 성장을 더욱 촉진하고 있습니다.
시장 제약 요인
견고한 성장 전망이 있는 반면, 도입 비용의 높음은 여전히 큰 과제로 남아 있습니다. 분산형 임상시험 인프라를 구축하려면 디지털 플랫폼, 사이버 보안, 원격의료 시스템, 물류, 전자 동의 솔루션, 원격 모니터링 기술에 대한 막대한 투자가 필요합니다. 또한 조직은 인재 양성, IT 통합, 규제 준수, 벤더 관리에도 투자해야 합니다. 서모피셔 사이언티피크(Thermo Fisher Scientific)의 조사에 따르면 응답자의 52.7%가 분산형 임상시험에서 여러 벤더의 기술을 활용하고 있다고 보고했으며, 이로 인해 업무의 복잡성과 도입 비용이 증가하고 있습니다.
시장 기회
신흥 경제국에서는 의료 인프라의 확대와 임상 연구 활동의 증가로 인해 큰 성장 기회가 창출되고 있습니다. 중국, 브라질, 인도, 멕시코 등의 국가들은 다양한 환자 집단과 비용 효율적인 연구 환경을 추구하는 제약 기업으로부터 더 많은 투자를 유치하고 있습니다. 미국 상무부 국제무역국에 따르면 2025년 브라질의 헬스케어 지출은 약 1,350억 달러에 달하며, 이는 분산형 임상시험 도입에 유리한 여건을 갖추고 있습니다. 디지털 헬스케어 인프라의 개선과 환자 중심 연구 모델에 대한 의식의 향상가 시장 확대를 더욱 가속화할 것으로 예상됩니다.
시장이 해결해야 할 과제
일부 개발도상국의 연구 인프라 부족이 여전히 시장 침투를 저해하고 있습니다. 많은 신흥 지역에서는 훈련된 임상 연구 전문가 부족, 일관성 없는 규제 체계, 미흡한 물류 네트워크, 그리고 디지털 헬스케어 도입이 제한적이라는 과제에 직면해 있습니다. 세계보건기구(WHO)에 따르면 브라질에서 2025년에 실시된 임상시험은 고작 2만 2,832건에 그쳐, 선진국과 신흥 국가의 헬스케어 연구 생태계 간 격차가 여실히 드러나고 있습니다.
세분화 분석
유형별로 보면 시장 세분화는 솔루션 및 서비스로 구분됩니다. 2025년에는 피험자 모집, 원격의료 조정, 전자 동의(eConsent) 도입, 원격 모니터링 및 분산형 임상시험 관리에 대한 수요가 증가함에 따라 서비스 부문이 시장을 주도했습니다. 반면, 솔루션 부문은 예측 기간 중 연평균 성장률(CAGR) 13.3%를 기록할 것으로 전망됩니다.
설계 형태별로는 시장이 ‘완전 분산형 임상시험’과 ‘하이브리드 분산형 임상시험’으로 분류됩니다. 2025년에는 기존의 시설 방문과 가상 헬스케어 기술을 결합하여 더 높은 유연성을 제공하는 ‘하이브리드 분산형 임상시험’이 가장 큰 점유율을 차지했습니다. ‘완전 분산형 임상시험’ 부문은 2034년까지 연평균 성장률(CAGR) 13.5%로 성장할 것으로 예상됩니다.
시험 단계별로는 대규모 임상 연구의 증가에 힘입어, 2025년에는 제3상 임상시험이 46.7%의 점유율을 차지하며 시장을 주도했습니다. 제4상 부문은 예측 기간 중 꾸준한 확대가 예상됩니다.
치료 분야별로는 2025년에도 종양학이 계속해서 주요 부문으로 자리매김할 것이며, 암 발병률 증가 및 분산형 종양학 임상시험 도입 확대를 배경으로 2026년에는 시장의 31.4%를 차지할 것으로 예상됩니다. 또한 순환기학 분야도 상당한 성장이 전망됩니다.
최종사용자별로는 제약·바이오기술 기업이 2025년에 가장 큰 점유율을 차지할 것이며, 분산형 임상 연구에 대한 투자 확대를 반영하여 2026년에는 시장의 50.3%를 차지할 것으로 예상됩니다. 의료기기 제조업체는 예측 기간 중 가장 빠른 성장세를 기록할 것으로 전망됩니다.
지역별 전망
북미는 계속해서 최대 지역 시장으로, 2025년에는 40억 6,000만 달러에 달했습니다. 한편, 미국 시장은 제약 업계의 막대한 연구개발(R&D) 지출과 첨단 디지털 헬스케어 인프라에 힘입어 2026년에는 42억 2,000만 달러에 달할 것으로 추정됩니다.
유럽은 중재적 임상시험의 확대와 분산형 연구 기술의 채택 확대에 힘입어 2026년에는 29억 7,000만 달러에 달하며, 연평균 성장률(CAGR) 12.6%로 성장할 것으로 예측됩니다.
아시아태평양은 중국, 일본, 인도의 헬스케어 투자 증가와 임상시험 활동 확대에 힘입어 2026년에는 22억 5,000만 달러에 달할 것으로 예상됩니다. 중국 단독으로는 9억 7,000만 달러, 일본과 인도는 각각 4억 3,000만 달러 및 2억 2,000만 달러에 달할 것으로 전망됩니다.
라틴아메리카는 2026년에 5억 9,000만 달러에 달할 것으로 예측되며, 중동 및 아프리카에서는 계속해서 완만한 성장이 예상되어 GCC 시장 규모는 2억 5,000만 달러로 추정됩니다.
목차
제1장 서론
제2장 개요
제3장 시장 역학
제4장 주요 인사이트
제5장 세계의 분산형 임상시험 시장 분석, 인사이트, 예측, 2021-2034년
제6장 북미의 분산형 임상시험 시장 분석, 인사이트, 예측, 2021-2034년
제7장 유럽의 분산형 임상시험 시장 분석, 인사이트, 예측, 2021-2034년
제8장 아시아태평양의 분산형 임상시험 시장 분석, 인사이트, 예측, 2021-2034년
제9장 라틴아메리카의 분산형 임상시험 시장 분석, 인사이트, 예측, 2021-2034년
제10장 중동 및 아프리카의 분산형 임상시험 시장 분석, 인사이트, 예측, 2021-2034년
제11장 경쟁 분석
KSA 26.09.16Growth Factors of decentralized clinical trials Market
The global decentralized clinical trials market was valued at USD 9.56 billion in 2025 and is projected to grow from USD 10.92 billion in 2026 to USD 29.37 billion by 2034, registering a CAGR of 13.2% during the forecast period. North America accounted for the largest market share of 42.46% in 2025, supported by widespread adoption of digital healthcare technologies, advanced clinical research infrastructure, and increasing investment in remote trial solutions.
Decentralized clinical trials (DCTs) allow some or all clinical trial activities to take place outside traditional research sites through digital platforms, telemedicine, wearable devices, remote patient monitoring, electronic consent (eConsent), and electronic patient-reported outcomes (ePRO). The growing prevalence of chronic diseases, increasing oncology and rare disease studies, rising patient-centric research models, and expanding use of artificial intelligence are accelerating the adoption of decentralized clinical trials worldwide.
Market Trends
The growing integration of artificial intelligence (AI) is transforming decentralized clinical trials by improving patient recruitment, trial matching, remote monitoring, predictive enrollment, and participant retention. AI-powered analytics enable sponsors to analyze electronic health records, genomic databases, and real-world evidence to identify eligible participants more efficiently. Telemedicine, wearable health devices, remote monitoring platforms, and digital data collection tools are also becoming standard components of decentralized trials, helping reduce patient burden while improving study efficiency. According to Tufts University School of Medicine, AI-assisted clinical trial activities delivered approximately 18% time savings in 2025, highlighting the increasing importance of intelligent digital solutions in clinical research.
Market Drivers
The increasing number of chronic disease, oncology, and rare disease clinical studies is one of the primary drivers supporting market expansion. These studies often require continuous patient monitoring, broader geographic participation, and long-term follow-up, making decentralized clinical trial models highly effective. According to the National Center for Biotechnology Information (NCBI), approximately 586,665 clinical trial studies were registered globally in 2026, reflecting the growing need for efficient trial management solutions. Rising healthcare expenditure, expansion of pharmaceutical research pipelines, personalized medicine initiatives, and increasing investments by major contract research organizations are further supporting market growth.
Market Restraints
Despite strong growth prospects, high implementation costs remain a significant challenge. Establishing decentralized clinical trial infrastructure requires substantial investment in digital platforms, cybersecurity, telehealth systems, logistics, electronic consent solutions, and remote monitoring technologies. Organizations must also invest in workforce training, IT integration, regulatory compliance, and vendor management. According to Thermo Fisher Scientific, 52.7% of respondents reported using technologies from multiple vendors in decentralized clinical trials, increasing operational complexity and implementation costs.
Market Opportunities
Emerging economies present substantial growth opportunities due to expanding healthcare infrastructure and increasing clinical research activities. Countries such as China, Brazil, India, and Mexico are attracting greater investments from pharmaceutical companies seeking diverse patient populations and cost-effective research environments. According to the International Trade Administration, Brazil's healthcare expenditure reached approximately USD 135.0 billion in 2025, creating favorable conditions for decentralized clinical trial adoption. Improved digital healthcare infrastructure and growing awareness of patient-centric research models are expected to further accelerate market expansion.
Market Challenges
Limited research infrastructure in several developing countries continues to restrict market penetration. Many emerging regions face shortages of trained clinical research professionals, inconsistent regulatory frameworks, inadequate logistics networks, and limited digital healthcare adoption. According to the World Health Organization, Brazil conducted only 22,832 clinical trials in 2025, highlighting the gap between developed and emerging healthcare research ecosystems.
Segmentation Analysis
Based on type, the market is segmented into solutions and services. The services segment dominated the market in 2025 due to increasing demand for patient recruitment, telehealth coordination, eConsent implementation, remote monitoring, and decentralized trial management. Meanwhile, the solutions segment is projected to register a CAGR of 13.3% during the forecast period.
By design, the market is categorized into fully decentralized trials and hybrid decentralized trials. Hybrid decentralized trials accounted for the largest share in 2025 because they combine traditional site visits with virtual healthcare technologies, offering greater flexibility. The fully decentralized trials segment is expected to grow at a CAGR of 13.5% through 2034.
Based on phase, Phase III clinical trials dominated the market with a 46.7% share in 2025, supported by increasing large-scale clinical studies. The Phase IV segment is anticipated to witness steady expansion during the forecast period.
By therapeutic area, oncology remained the leading segment in 2025 and is expected to account for 31.4% of the market in 2026, driven by the increasing incidence of cancer and rising adoption of decentralized oncology trials. Cardiology is also projected to experience significant growth.
Based on end user, pharmaceutical and biotechnological companies held the dominant share in 2025 and are expected to account for 50.3% of the market in 2026, reflecting increasing investments in decentralized clinical research. Medical device companies are expected to record the fastest growth during the forecast period.
Regional Outlook
North America remained the largest regional market, reaching USD 4.06 billion in 2025, while the U.S. market is estimated at USD 4.22 billion in 2026, supported by strong pharmaceutical R&D spending and advanced digital healthcare infrastructure.
Europe is projected to reach USD 2.97 billion in 2026, growing at a CAGR of 12.6%, driven by expanding interventional clinical studies and rising adoption of decentralized research technologies.
Asia Pacific is expected to achieve USD 2.25 billion in 2026, supported by increasing healthcare investments and growing clinical trial activity across China, Japan, and India. China alone is projected to generate USD 0.97 billion, while Japan and India are expected to reach USD 0.43 billion and USD 0.22 billion, respectively.
Latin America is projected to reach USD 0.59 billion in 2026, while the Middle East & Africa continues to witness gradual expansion, with the GCC market estimated at USD 0.25 billion.
Competitive Landscape
The decentralized clinical trials market remains highly competitive, with major companies focusing on technology expansion, AI integration, acquisitions, and strategic collaborations. Leading participants include IQVIA, ICON plc, Thermo Fisher Scientific Inc., Parexel International, Medpace, Labcorp, Oracle, Signant Health, Fortrea, and Tecex Medical. Recent developments include Labcorp's collaboration with Hawthorne Effect to enhance decentralized trial capabilities, Signant Health's partnership with IQVIA for expanding eClinical solutions, and Cenmed's collaboration with Curavit Clinical Research to strengthen decentralized clinical trial logistics.
Conclusion
The decentralized clinical trials market is poised for strong expansion as pharmaceutical companies increasingly adopt digital, patient-centric research models. Growing use of artificial intelligence, telemedicine, wearable technologies, and remote monitoring is transforming clinical trial operations by improving patient recruitment, engagement, and study efficiency. Although high implementation costs and infrastructure limitations remain challenges, rising healthcare investments, expanding clinical research in emerging economies, and continuous technological innovation are expected to drive sustained market growth. With the market projected to increase from USD 9.56 billion in 2025 to USD 29.37 billion by 2034, decentralized clinical trials are expected to become an integral component of the future clinical research ecosystem.
Segmentation By Type, Design, Phase, Therapeutic Area, End User, and Region
By Type * Solutions
- Services
By Design * Fully Decentralized Trials
- Hybrid Decentralized Trials
By Phase * Phase I
- Phase II
- Phase III
- Phase IV
By Therapeutic Area * Oncology
- Infectious Diseases
- Neurology
- Cardiology
- Others
By End User * Pharmaceutical & Biotechnological Companies
- Medical Device Companies
- CROs
- Others
By Region * North America (By Type, By Design, By Phase, By Therapeutic Area, By End User, and by Country)
- U.S. (By Design)
- Canada (By Design)
- Europe (By Type, By Design, By Phase, By Therapeutic Area, By End User, and by Country/Sub-region)
- U.K. (By Design)
- Germany (By Design)
- France (By Design)
- Italy (By Design)
- Spain (By Design)
- Scandinavia (By Design)
- Rest of Europe (By Design)
- Asia Pacific (By Type, By Design, By Phase, By Therapeutic Area, By End User, and by Country/Sub-region)
- China (By Design)
- Japan (By Design)
- India (By Design)
- Australia (By Design)
- Southeast Asia (By Design)
- Rest of Asia Pacific (By Design)
- Latin America (By Type, By Design, By Phase, By Therapeutic Area, By End User, and by Country/Sub-region)
- Brazil (By Design)
- Mexico (By Design)
- Rest of Latin America (By Design)
- Middle East & Africa (By Type, By Design, By Phase, By Therapeutic Area, By End User, and by Country/Sub-region)
- GCC (By Design)
- South Africa (By Design)
- Rest of the Middle East & Africa (By Design)
Table of Content
1. Introduction
- 1.1. Research Scope
- 1.2. Market Segmentation
- 1.3. Research Methodology
2. Executive Summary
3. Market Dynamics
- 3.1. Market Drivers
- 3.2. Market Restraints
- 3.3. Market Opportunities
- 3.4. Market Challenges
- 3.5. Market Trends
4. Key Insights
- 4.1. Number of Clinical Trials, Key Countries/Regions, 2025
- 4.2. Overview of R&D Expenditures, Key Players
- 4.3. Key Industry Developments - Mergers, Acquisitions & Partnerships
5. Global Decentralized Clinical Trials Market Analysis, Insights and Forecast, 2021-2034
- 5.1. Market Analysis, Insights and Forecast - By Type
- 5.1.1. Solutions
- 5.1.2. Services
- 5.2. Market Analysis, Insights and Forecast - By Design
- 5.2.1. Fully Decentralized Trials
- 5.2.2. Hybrid Decentralized Trials
- 5.3. Market Analysis, Insights and Forecast - By Phase
- 5.3.1. Phase I
- 5.3.2. Phase II
- 5.3.3. Phase III
- 5.3.4. Phase IV
- 5.4. Market Analysis, Insights and Forecast - By Therapeutic Area
- 5.4.1. Oncology
- 5.4.2. Infectious Diseases
- 5.4.3. Neurology
- 5.4.4. Cardiology
- 5.4.5. Others
- 5.5. Market Analysis, Insights and Forecast - By End User
- 5.5.1. Pharmaceutical & Biotechnological Companies
- 5.5.2. Medical Device Companies
- 5.5.3. CROs
- 5.5.4. Others
- 5.6. Market Analysis, Insights and Forecast - By Region
- 5.6.1. North America
- 5.6.2. Europe
- 5.6.3. Asia Pacific
- 5.6.4. Latin America
- 5.6.5. Middle East & Africa
6. North America Decentralized Clinical Trials Market Analysis, Insights and Forecast, 2021-2034
- 6.1. Market Analysis, Insights and Forecast - By Type
- 6.1.1. Solutions
- 6.1.2. Services
- 6.2. Market Analysis, Insights and Forecast - By Design
- 6.2.1. Fully Decentralized Trials
- 6.2.2. Hybrid Decentralized Trials
- 6.3. Market Analysis, Insights and Forecast - By Phase
- 6.3.1. Phase I
- 6.3.2. Phase II
- 6.3.3. Phase III
- 6.3.4. Phase IV
- 6.4. Market Analysis, Insights and Forecast - By Therapeutic Area
- 6.4.1. Oncology
- 6.4.2. Infectious Diseases
- 6.4.3. Neurology
- 6.4.4. Cardiology
- 6.4.5. Others
- 6.5. Market Analysis, Insights and Forecast - By End User
- 6.5.1. Pharmaceutical & Biotechnological Companies
- 6.5.2. Medical Device Companies
- 6.5.3. CROs
- 6.5.4. Others
- 6.6. Market Analysis, Insights and Forecast - By Country
- 6.6.1. U.S.
- 6.6.1.1. By Design
- 6.6.2. Canada
- 6.6.2.1. By Design
- 6.6.1. U.S.
7. Europe Decentralized Clinical Trials Market Analysis, Insights and Forecast, 2021-2034
- 7.1. Market Analysis, Insights and Forecast - By Type
- 7.1.1. Solutions
- 7.1.2. Services
- 7.2. Market Analysis, Insights and Forecast - By Design
- 7.2.1. Fully Decentralized Trials
- 7.2.2. Hybrid Decentralized Trials
- 7.3. Market Analysis, Insights and Forecast - By Phase
- 7.3.1. Phase I
- 7.3.2. Phase II
- 7.3.3. Phase III
- 7.3.4. Phase IV
- 7.4. Market Analysis, Insights and Forecast - By Therapeutic Area
- 7.4.1. Oncology
- 7.4.2. Infectious Diseases
- 7.4.3. Neurology
- 7.4.4. Cardiology
- 7.4.5. Others
- 7.5. Market Analysis, Insights and Forecast - By End User
- 7.5.1. Pharmaceutical & Biotechnological Companies
- 7.5.2. Medical Device Companies
- 7.5.3. CROs
- 7.5.4. Others
- 7.6. Market Analysis, Insights and Forecast - By Country/Sub-region
- 7.6.1. U.K.
- 7.6.1.1. By Design
- 7.6.2. Germany
- 7.6.2.1. By Design
- 7.6.3. France
- 7.6.3.1. By Design
- 7.6.4. Spain
- 7.6.4.1. By Design
- 7.6.5. Italy
- 7.6.5.1. By Design
- 7.6.6. Scandinavia
- 7.6.6.1. By Design
- 7.6.7. Rest of Europe
- 7.6.7.1. By Design
- 7.6.1. U.K.
8. Asia Pacific Decentralized Clinical Trials Market Analysis, Insights and Forecast, 2021-2034
- 8.1. Market Analysis, Insights and Forecast - By Type
- 8.1.1. Solutions
- 8.1.2. Services
- 8.2. Market Analysis, Insights and Forecast - By Design
- 8.2.1. Fully Decentralized Trials
- 8.2.2. Hybrid Decentralized Trials
- 8.3. Market Analysis, Insights and Forecast - By Phase
- 8.3.1. Phase I
- 8.3.2. Phase II
- 8.3.3. Phase III
- 8.3.4. Phase IV
- 8.4. Market Analysis, Insights and Forecast - By Therapeutic Area
- 8.4.1. Oncology
- 8.4.2. Infectious Diseases
- 8.4.3. Neurology
- 8.4.4. Cardiology
- 8.4.5. Others
- 8.5. Market Analysis, Insights and Forecast - By End User
- 8.5.1. Pharmaceutical & Biotechnological Companies
- 8.5.2. Medical Device Companies
- 8.5.3. CROs
- 8.5.4. Others
- 8.6. Market Analysis, Insights and Forecast - By Country/Sub-region
- 8.6.1. Japan
- 8.6.1.1. By Design
- 8.6.2. Australia
- 8.6.2.1. By Design
- 8.6.3. China
- 8.6.3.1. By Design
- 8.6.4. India
- 8.6.4.1. By Design
- 8.6.5. Southeast Asia
- 8.6.5.1. By Design
- 8.6.6. Rest of Asia Pacific
- 8.6.6.1. By Design
- 8.6.1. Japan
9. Latin America Decentralized Clinical Trials Market Analysis, Insights and Forecast, 2021-2034
- 9.1. Market Analysis, Insights and Forecast - By Type
- 9.1.1. Solutions
- 9.1.2. Services
- 9.2. Market Analysis, Insights and Forecast - By Design
- 9.2.1. Fully Decentralized Trials
- 9.2.2. Hybrid Decentralized Trials
- 9.3. Market Analysis, Insights and Forecast - By Phase
- 9.3.1. Phase I
- 9.3.2. Phase II
- 9.3.3. Phase III
- 9.3.4. Phase IV
- 9.4. Market Analysis, Insights and Forecast - By Therapeutic Area
- 9.4.1. Oncology
- 9.4.2. Infectious Diseases
- 9.4.3. Neurology
- 9.4.4. Cardiology
- 9.4.5. Others
- 9.5. Market Analysis, Insights and Forecast - By End User
- 9.5.1. Pharmaceutical & Biotechnological Companies
- 9.5.2. Medical Device Companies
- 9.5.3. CROs
- 9.5.4. Others
- 9.6. Market Analysis, Insights and Forecast - By Country/Sub-region
- 9.6.1. Brazil
- 9.6.1.1. By Design
- 9.6.2. Mexico
- 9.6.2.1. By Design
- 9.6.3. Rest of Latin America
- 9.6.3.1. By Design
- 9.6.1. Brazil
10. Middle East & Africa Decentralized Clinical Trials Market Analysis, Insights and Forecast, 2021-2034
- 10.1. Market Analysis, Insights and Forecast - By Type
- 10.1.1. Solutions
- 10.1.2. Services
- 10.2. Market Analysis, Insights and Forecast - By Design
- 10.2.1. Fully Decentralized Trials
- 10.2.2. Hybrid Decentralized Trials
- 10.3. Market Analysis, Insights and Forecast - By Phase
- 10.3.1. Phase I
- 10.3.2. Phase II
- 10.3.3. Phase III
- 10.3.4. Phase IV
- 10.4. Market Analysis, Insights and Forecast - By Therapeutic Area
- 10.4.1. Oncology
- 10.4.2. Infectious Diseases
- 10.4.3. Neurology
- 10.4.4. Cardiology
- 10.4.5. Others
- 10.5. Market Analysis, Insights and Forecast - By End User
- 10.5.1. Pharmaceutical & Biotechnological Companies
- 10.5.2. Medical Device Companies
- 10.5.3. CROs
- 10.5.4. Others
- 10.6. Market Analysis, Insights and Forecast - By Country/Sub-region
- 10.6.1. GCC
- 10.6.1.1. By Design
- 10.6.2. South Africa
- 10.6.2.1. By Design
- 10.6.3. Rest of the Middle East & Africa
- 10.6.3.1. By Design
- 10.6.1. GCC
11. Competitive Analysis
- 11.1. Global Market Share Analysis (2025)
- 11.2. Company Profiles
- 11.2.1. IQVIA
- 11.2.2. ICON plc
- 11.2.3. Thermo Fisher Scientific Inc.
- 11.2.4. Parexel International (MA) Corporation
- 11.2.5. Medpace
- 11.2.6. Lacorp
- 11.2.7. Oracle
- 11.2.8. Signant Health
- 11.2.9. Fortrea
- 11.2.10. Tecex Medical
